Dupilumab May Benefit Patients Hospitalized With Moderate-To-Severe COVID-19, Trial Suggests

HealthDay (8/16) reports that “early research suggests that dupilumab, a monoclonal antibody used to treat asthma and eczema, may benefit patients hospitalized with moderate-to-severe COVID-19, according to” a “phase 2a randomized, double-blind, placebo-c...